MOREPENLAB115.50

Morepen Laboratories Limited

· Pharma & Health
₹ CrorePeersIOLCPINNOVACAPFDCORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹6,328 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
MOREPENLAB
FY26
IOLCP
FY26
INNOVACAP
FY26
FDC
FY26
Peer
Median
Valuation — at last close
P/E66.76×45.20×47.30×20.03×45.20× +48%
P/B5.07×3.46×6.11×2.27×3.46× +47%
EV/EBITDA51.49×23.37×28.68×14.79×23.37× +120%
Market Cap₹6,328 Cr₹6,223 Cr₹6,667 Cr₹5,640 Cr₹6,223 Cr +2%
Growth
Revenue CAGR 3Y8.40%1.51%6.77%4.14% +103%
Revenue CAGR 5Y8.73%10.24%10.24% -15%
Net Income CAGR 3Y34.87%-0.36%13.23%6.44% +442%
Revenue YoY (latest Q)34.07%37.08%33.94%2.97%33.94% +0%
Net Income YoY (latest Q)424.73%89.80%42.27%9.18%42.27% +905%
Profitability
EBITDA Margin6.96%11.60%14.90%15.94%14.90% -53%
Net Income Margin5.25%5.94%8.65%12.96%8.65% -39%
Return on Common Equity7.61%7.65%12.92%11.32%11.32% -33%
Return on Capital Employed6.17%9.95%14.73%11.23%11.23% -45%
Return on Assets4.90%5.32%7.67%9.64%7.67% -36%
Credit & Quality
Total Debt/Equity0.16×0.07×0.32×0.00×0.07× +129%
Interest Coverage5.43×12.97×11.70×57.54×12.97× -58%
Scale — latest FY
Revenue / Total Income₹1,806 Cr₹2,319 Cr₹1,630 Cr₹2,171 Cr₹2,171 Cr -17%
Net Income₹94.9 Cr₹138 Cr₹141 Cr₹281 Cr₹141 Cr -33%
Total Assets₹1,936 Cr₹2,587 Cr₹1,837 Cr₹2,919 Cr₹2,587 Cr -25%
EPS₹1.73₹4.69₹24.63₹17.29₹17.29 -90%
Book Value per Share₹22.76₹61.27₹190.61₹152.64₹152.64 -85%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.